Bevacizumab is Effective for Recurrent Papillary Tumor of the Pineal Region: First Report

Cohen, Adam L.; Salzman, Karen L.; Palmer, Cheryl A.; Jensen, Randy L.; Colman, Howard

doi:10.1159/000354753

Cited by 17 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patients received 50-and 55 -Gy radiation, as well as chemotherapy. Although local recurrence occurred twice, the patients were well and alive for 218 and 240 months after presentation, respectively (21)(22)(23)(24). There are other reports of PTPR in patients who did not undergo complete tumor resection and remained well for a long period (84 and 108 months, respectively) (9, 25).…”

Section: U N C O R R E C T E D P R O O Fmentioning

confidence: 81%

“…The highest RT dose was reported by Cohen, who irradiated the patient up to 59.4 Gy in 33 fractions. The patient showed parenchymal recurrence seven months after therapy (23). In another report, the patient received 30 -Gy RT in ten fractions and remained alive for 56 months (28).…”

Section: U N C O R R E C T E D P R O O Fmentioning

confidence: 87%

“…Metastasis appeared seven months after the primary tumor treatment (23). Few patients (only four cases) had died at the time of report.…”

Section: U N C O R R E C T E D P R O O Fmentioning

confidence: 94%

“…On the other hand, bevacizumab, as a single agent, was partially effective against PTPR. The tumor decreased in size and became stable for 13 months (it increased again afterwards) (23).…”

Section: U N C O R R E C T E D P R O O Fmentioning

confidence: 96%

See 3 more Smart Citations

Papillary Tumor of the Pineal Region: Clinical Presentations, Prognostic Factors, Treatments, and Outcomes

Nasrollahi

Kadkhodaei

Hamedi

et al. 2016

Rep Radiother Oncol

View full text Add to dashboard Cite

The pineal region is a rare site for primary tumors of the central nervous system. Papillary tumor of the pineal region (PTPR) is a relatively new phenomenon in this region. Considering the rarity of this tumor, the clinical course, treatment, and outcomes are not well studied. In the present study, we searched PubMed for relevant articles. A total of 72 articles were retrieved from PubMed. The exclusion criteria were autopsy and archive series, animal studies, and reports without clinical data. We had no access to the full -text of some articles; accordingly, 19 articles were excluded from the analysis. Data from 53 reports, including 50 case reports and three case series (a total of 73 patients), were collected and analyzed. The patients' mean age was 33.5 (± 15.4) years. Forty -two cases were male and 31 were female. The most common symptom was headache in patients (80%). Other common symptoms included visual complaints (40%), nausea (31%), memory loss (7%), Parinaud's syndrome (4%), and impaired gait (2%). Among 73 patients, 32 had undergone complete tumor resection. Twenty -nine patients had received conventional external beam radiotherapy, stereotactic radiosurgery (n, 10), brachytherapy (n, 5), and proton therapy (n, 1). Eight patients received no adjuvant therapy, and data presented in other reports were incomplete. Among the patients (n, 73), 11 received chemotherapy. Fifty patients had no evidence of recurrence at the time of report, while three patients had died. Local recurrence was the most common pattern of relapse (28%); nonetheless, parenchymal and meningeal involvement was also observed. The median disease -free survival (DFS) was 24 months, while fiveand ten -year DFS rates were 50.1% and 25.0%, respectively. The median overall survival was 24 months. Generally, PTPR has an indolent course with a tendency towards local recurrence; nonetheless, an aggressive clinical course, associated with parenchymal and meningeal metastases, is well established.

show abstract

Section: U N C O R R E C T E D P R O O Fmentioning

confidence: 81%

Section: U N C O R R E C T E D P R O O Fmentioning

confidence: 87%

“…Metastasis appeared seven months after the primary tumor treatment (23). Few patients (only four cases) had died at the time of report.…”

Section: U N C O R R E C T E D P R O O Fmentioning

confidence: 94%

“…On the other hand, bevacizumab, as a single agent, was partially effective against PTPR. The tumor decreased in size and became stable for 13 months (it increased again afterwards) (23).…”

Section: U N C O R R E C T E D P R O O Fmentioning

confidence: 96%

See 2 more Smart Citations

Papillary Tumor of the Pineal Region: Clinical Presentations, Prognostic Factors, Treatments, and Outcomes

Nasrollahi

Kadkhodaei

Hamedi

et al. 2016

Rep Radiother Oncol

View full text Add to dashboard Cite

show abstract

“…The biological behavior of PTPR is variable and may correspond to the WHO grades II or III [4]. This rare tumor has been described in fewer than 100 cases [5,6]. The optimal treatment options have not been established yet [4,[7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Papillary tumor of the pineal region. Report of two cases and literature review

Koziarski

Grala

Skrobowska

2014

Neurologia i Neurochirurgia Polska

View full text Add to dashboard Cite

Papillary tumor of the pineal region (PTPR) was introduced to the WHO classification in 2007. This rare tumor of little known natural history and unpredictable behavior was described in fewer than 100 cases. Its optimal treatment is not established yet. We report another two cases of PTPR in whom tumors were totally removed via supracerebellar infratentorial approach and both were treated with radiotherapy. In a 37-year-old man the operation was delayed 6 years after the first tumor diagnosis and subsequent shunt placement. He has no complaints 10 years after the onset of the disease. A 45-year-old woman has no complaints 24 months after surgery. Our experience and the data from literature indicate that a total tumor removal is the major prognostic factor.

show abstract

Chemotherapy

Aldea¹,

Olteanu²

2020

Pineal Region Lesions

View full text Add to dashboard Cite

Bevacizumab is Effective for Recurrent Papillary Tumor of the Pineal Region: First Report

Cited by 17 publications

References 21 publications

Papillary Tumor of the Pineal Region: Clinical Presentations, Prognostic Factors, Treatments, and Outcomes

Papillary Tumor of the Pineal Region: Clinical Presentations, Prognostic Factors, Treatments, and Outcomes

Papillary tumor of the pineal region. Report of two cases and literature review

Chemotherapy

Contact Info

Product

Resources

About